Antiangiogenic therapy in lung cancer: Focus on vascular endothelial growth factor pathway

Grzegorz Korpanty; Elizabeth Smyth; Laura A. Sullivan; Rolf A. Brekken; Desmond N. Carney

doi:10.1258/ebm.2009.009191

Antiangiogenic therapy in lung cancer: Focus on vascular endothelial growth factor pathway

Grzegorz Korpanty, Elizabeth Smyth, Laura A. Sullivan, Rolf A. Brekken, Desmond N. Carney

Research output: Contribution to journal › Short survey › peer-review

41 Scopus citations

Abstract

Lung cancer (LC) is a leading cause of death worldwide. Recent advances in chemotherapeutic agents have not yielded any significant improvement in the prognosis of patients with LC. The five-year survival rate for all combined disease stages remains about 15%. For this reason, new therapies such as those that inhibit tumor angiogenesis or block activity of growth factor receptors are of special interest in this group of patients. In this review we will summarize the most recent clinical data on biologic therapies that inhibit tumor angiogenesis in LC, focusing on those that are most clinically relevant.

Original language	English (US)
Pages (from-to)	3-9
Number of pages	7
Journal	Experimental Biology and Medicine
Volume	235
Issue number	1
DOIs	https://doi.org/10.1258/ebm.2009.009191
State	Published - Jan 2010

Keywords

Angiogenesis
Antiangiogenesis
Lung cancer
VEGF

ASJC Scopus subject areas

Biochemistry, Genetics and Molecular Biology(all)

Access to Document

10.1258/ebm.2009.009191

Cite this

@article{3ac103e8ffb14cd28b7e1db06b5a8887,

title = "Antiangiogenic therapy in lung cancer: Focus on vascular endothelial growth factor pathway",

abstract = "Lung cancer (LC) is a leading cause of death worldwide. Recent advances in chemotherapeutic agents have not yielded any significant improvement in the prognosis of patients with LC. The five-year survival rate for all combined disease stages remains about 15%. For this reason, new therapies such as those that inhibit tumor angiogenesis or block activity of growth factor receptors are of special interest in this group of patients. In this review we will summarize the most recent clinical data on biologic therapies that inhibit tumor angiogenesis in LC, focusing on those that are most clinically relevant.",

keywords = "Angiogenesis, Antiangiogenesis, Lung cancer, VEGF",

author = "Grzegorz Korpanty and Elizabeth Smyth and Sullivan, {Laura A.} and Brekken, {Rolf A.} and Carney, {Desmond N.}",

year = "2010",

month = jan,

doi = "10.1258/ebm.2009.009191",

language = "English (US)",

volume = "235",

pages = "3--9",

journal = "Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N. Y.)",

issn = "1535-3702",

publisher = "SAGE Publications Ltd",

number = "1",

}

TY - JOUR

T1 - Antiangiogenic therapy in lung cancer

T2 - Focus on vascular endothelial growth factor pathway

AU - Korpanty, Grzegorz

AU - Smyth, Elizabeth

AU - Sullivan, Laura A.

AU - Brekken, Rolf A.

AU - Carney, Desmond N.

PY - 2010/1

Y1 - 2010/1

N2 - Lung cancer (LC) is a leading cause of death worldwide. Recent advances in chemotherapeutic agents have not yielded any significant improvement in the prognosis of patients with LC. The five-year survival rate for all combined disease stages remains about 15%. For this reason, new therapies such as those that inhibit tumor angiogenesis or block activity of growth factor receptors are of special interest in this group of patients. In this review we will summarize the most recent clinical data on biologic therapies that inhibit tumor angiogenesis in LC, focusing on those that are most clinically relevant.

AB - Lung cancer (LC) is a leading cause of death worldwide. Recent advances in chemotherapeutic agents have not yielded any significant improvement in the prognosis of patients with LC. The five-year survival rate for all combined disease stages remains about 15%. For this reason, new therapies such as those that inhibit tumor angiogenesis or block activity of growth factor receptors are of special interest in this group of patients. In this review we will summarize the most recent clinical data on biologic therapies that inhibit tumor angiogenesis in LC, focusing on those that are most clinically relevant.

KW - Angiogenesis

KW - Antiangiogenesis

KW - Lung cancer

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=76749101884&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76749101884&partnerID=8YFLogxK

U2 - 10.1258/ebm.2009.009191

DO - 10.1258/ebm.2009.009191

M3 - Short survey

C2 - 20404013

AN - SCOPUS:76749101884

SN - 1535-3702

VL - 235

SP - 3

EP - 9

JO - Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N. Y.)

JF - Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N. Y.)

IS - 1

ER -

Antiangiogenic therapy in lung cancer: Focus on vascular endothelial growth factor pathway

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this